Pediatric indication for SOBI’s Kineret from UK’s MHRA

Kineret (anakinra), from Nordic biotech firm Swedish Orphan Biovitrum (STO: SOBI), has been licensed by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for children and babies from eight months old with cryopyrin-associated periodic syndromes (CAPS).

CAPS is an umbrella term for a number of ultra-rare, life-long, severely debilitating autoinflammatory diseases which cause rash, headache, fever, joint pain and other inflammatory symptoms. It affects around one in one million people in the UK and patients suffer substantial pain and progressive reduction in their quality of life. The most severe form of the condition causes chronic inflammation of the meninges (aseptic meningitis).